ImmunityBio (IBRX) Assets Average (2015 - 2026)
ImmunityBio (IBRX) posted quarterly Assets Average of $574.3 million for Q1 2026, up 67.26% year-over-year from $343.3 million in Q1 2025, and up 12.5% quarter-over-quarter from $510.4 million in Q4 2025.
ImmunityBio (IBRX) Assets Average (2015 - 2026) Analysis & Trends
ImmunityBio (IBRX) has reported Assets Average for 12 consecutive years, with $574.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 67.26% year-over-year to $574.3 million; the TTM figure through Mar 2026 stood at $574.3 million (up 67.26% YoY), while the FY2025 annual figure was $442.4 million, changed 0.29% from the prior year.
- Assets Average advanced to $574.3 million in Q1 2026 per IBRX's latest filing, from $510.4 million in the prior quarter.
- Across five years, Assets Average topped out at $574.3 million in Q1 2026 and bottomed at $317.3 million in Q2 2023.
- Historically, Assets Average has averaged $404.2 million across 5 years, with a median of $373.8 million in 2024.
- Annual changes were most pronounced in 2022 — Assets Average jumped 99.28% — and 2025, when it retreated 24.13%.
- ImmunityBio's Assets Average stood at $357.6 million in 2022, then soared by 30.98% to $468.4 million in 2023, then retreated by 20.21% to $373.8 million in 2024, then soared by 36.57% to $510.4 million in 2025, then grew by 12.5% to $574.3 million in 2026.
- Business Quant data shows IBRX's Assets Average at $574.3 million in Q1 2026, $510.4 million in Q4 2025, and $460.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | ImmunityBio | 7.97 Bn | 7.62 Bn | 50.94 Mn | 637.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 637.57 Mn |
| Mar 31, 2026 | 574.27 Mn |
| Dec 31, 2025 | 510.44 Mn |
| Sep 30, 2025 | 460.53 Mn |
| Jun 30, 2025 | 352.92 Mn |
| Mar 31, 2025 | 343.35 Mn |
| Dec 31, 2024 | 373.75 Mn |
| Sep 30, 2024 | 404.45 Mn |
| Jun 30, 2024 | 422.50 Mn |
| Mar 31, 2024 | 452.57 Mn |
| Dec 31, 2023 | 468.44 Mn |
| Sep 30, 2023 | 361.82 Mn |
| Jun 30, 2023 | 317.31 Mn |
| Mar 31, 2023 | 352.88 Mn |
| Dec 31, 2022 | 357.65 Mn |
| Sep 30, 2022 | 335.33 Mn |
| Jun 30, 2022 | 353.65 Mn |
| Mar 31, 2022 | 429.25 Mn |
| Dec 31, 2021 | 341.67 Mn |
| Sep 30, 2021 | 230.36 Mn |